<p>在澳大利亚市场面临贸易放缓和投资者谨慎的背景下，识别具有显著内部持股的成长型公司可以为潜在投资机会提供有价值的见解。在这种信心受到地缘政治不确定性影响的环境中，强大的内部承诺的股票可能表明对公司长期前景的更高信任度。</p>
<h3>澳大利亚内部持股高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部持股高的快速成长 ASX 公司筛选器中的 93 只股票的完整列表。</p>
<p>我们将查看筛选工具中一些最佳选择。</p>
<h2>Aurelia Metals (ASX:AMI)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Aurelia Metals Limited 是一家澳大利亚公司，专注于矿产资源的勘探和生产，市值为 4.5699 亿澳元。</p>
<p><strong>运营：</strong> 公司的收入主要来自于 Peak 矿（2.4513 亿澳元）、Dargues 矿（7390 万澳元）和 Hera 矿（598 万澳元）的运营。</p>
<p><strong>内部持股：</strong> 23.9%</p>
<p>Aurelia Metals 作为一家具有实质内部持股的成长型公司展现出良好前景，最近几个月内部人士的显著买入证明了这一点。公司已恢复盈利，报告截至 2024 年 12 月的半年净收入为 1795 万澳元，而之前则出现亏损。尽管黄金和白银的产量下降，但铜的产量显著增加。分析师预测年盈利增长将达到 23.6%，超过澳大利亚市场预期的 11.7% 的增长率。</p>
<ul>
<li>解锁我们对 Aurelia Metals 股票分析的全面见解，详见本成长报告。</li>
<li>我们编制的估值报告表明，Aurelia Metals 当前的价格可能相对适中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 4 月的 ASX:AMI 盈利和收入增长</p>
<h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clarity Pharmaceuticals Ltd 是一家临床阶段的放射药物公司，专注于在澳大利亚和美国研发放射药物产品，市值为 5.3987 亿澳元。</p>
<p><strong>运营：</strong> 公司的收入部分来自放射药物开发，产生 1078 万澳元的收入。</p>
<p><strong>内部持股：</strong> 17.8%</p>
<p>Clarity Pharmaceuticals 展现出强大的增长潜力，得益于其创新的 Cu-SAR-bisPSMA 前列腺癌治疗平台。最近的试验进展显示出良好的疗效和安全性，重度预处理参与者的 PSA 显著降低。FDA 的快速通道认证支持加速开发。尽管截至 2024 年 12 月的半年净亏损为 2358 万澳元，但收入从 652 万澳元增长至 1094 万澳元，预测显示收入增长迅速，超过市场平均水平。</p>
<ul>
<li>在我们的盈利增长报告中更深入地了解 Clarity Pharmaceuticals 的潜力。</li>
<li>我们的估值报告显示 Clarity Pharmaceuticals 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 4 月的 ASX:CU6 盈利和收入增长</p>
<h2>IperionX (ASX:IPX)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> IperionX Limited 专注于在美国的矿产资源勘探和开发，市值约为 9 亿澳元。</p>
<p><strong>运营：</strong> 提供的文本中未具体说明 IperionX Limited 的收入部分。</p>
<p><strong>内部持股：</strong> 19.2%</p>
<p>IperionX 凭借其在田纳西州的 Titan 关键矿产项目和战略性美国合作伙伴关系，正处于显著增长的有利位置，包括获得 4710 万美元的政府奖励以增强钛供应链。尽管最近股东稀释和截至 2024 年 12 月的半年净亏损为 1624 万美元，IperionX 的收入预计将迅速增长，超过市场平均水平，预计在三年内实现盈利，得益于创新技术和实质内部持股。</p>
<ul>
<li>点击这里发现 IperionX 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们的全面估值报告提出 IperionX 的定价可能高于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown"/></p>
<p>截至 2025 年 4 月的 ASX:IPX 持股结构</p>
<h2>接下来该怎么办？</h2>
<ul>
<li>点击进入，开始探索其余 90 家内部持股高的快速成长 ASX 公司。</li>
<li>考虑其他策略？这项技术可能取代计算机：发现 22 只股票正在努力使量子计算成为现实。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
<p>如果您想交易 IperionX，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

<p>澳大利亚市场目前因全球紧张局势面临贸易放缓和投资者谨慎。识别具有显著内部持股的成长型公司可以提供投资洞察。值得注意的公司包括 Aurelia Metals（23.9% 内部持股，23.6% 盈利增长）、Clarity Pharmaceuticals（17.8% 内部持股，快速收入增长）和 IperionX（19.2% 内部持股，预计三年内实现盈利）。尽管近期面临挑战，这些公司仍显示出潜力，内部持股表明对其长期前景的信心</p>

<p>As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects.</p>
<div class="lb-trans"><p>在澳大利亚市场面临贸易放缓和投资者谨慎的背景下，识别具有显著内部持股的成长型公司可以为潜在投资机会提供有价值的见解。在这种信心受到地缘政治不确定性影响的环境中，强大的内部承诺的股票可能表明对公司长期前景的更高信任度。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Australia</h3>
<div class="lb-trans"><h3>澳大利亚内部持股高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部持股高的快速成长 ASX 公司筛选器中的 93 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中一些最佳选择。</p>
</div><h2>Aurelia Metals (ASX:AMI)</h2>
<div class="lb-trans"><h2>Aurelia Metals (ASX:AMI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aurelia Metals Limited 是一家澳大利亚公司，专注于矿产资源的勘探和生产，市值为 4.5699 亿澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million).</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自于 Peak 矿（2.4513 亿澳元）、Dargues 矿（7390 万澳元）和 Hera 矿（598 万澳元）的运营。</p>
</div><p><strong>Insider Ownership:</strong> 23.9%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 23.9%</p>
</div><p>Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%.</p>
<div class="lb-trans"><p>Aurelia Metals 作为一家具有实质内部持股的成长型公司展现出良好前景，最近几个月内部人士的显著买入证明了这一点。公司已恢复盈利，报告截至 2024 年 12 月的半年净收入为 1795 万澳元，而之前则出现亏损。尽管黄金和白银的产量下降，但铜的产量显著增加。分析师预测年盈利增长将达到 23.6%，超过澳大利亚市场预期的 11.7% 的增长率。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Aurelia Metals stock in this growth report.</li>
<li>The valuation report we've compiled suggests that Aurelia Metals' current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Aurelia Metals 股票分析的全面见解，详见本成长报告。</li>
<li>我们编制的估值报告表明，Aurelia Metals 当前的价格可能相对适中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth"/></p>
<p>ASX:AMI Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:AMI 盈利和收入增长</p>
</div><h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
<div class="lb-trans"><h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clarity Pharmaceuticals Ltd 是一家临床阶段的放射药物公司，专注于在澳大利亚和美国研发放射药物产品，市值为 5.3987 亿澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分来自放射药物开发，产生 1078 万澳元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 17.8%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 17.8%</p>
</div><p>Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovative Cu-SAR-bisPSMA platform for prostate cancer treatment. Recent trial advancements show promising efficacy and safety, with significant PSA reductions in heavily pre-treated participants. The FDA's Fast Track Designation supports accelerated development. Despite a net loss of A$23.58 million for the half-year ending December 2024, revenue grew to A$10.94 million from A$6.52 million year-over-year, with forecasts indicating rapid revenue growth exceeding market averages.</p>
<div class="lb-trans"><p>Clarity Pharmaceuticals 展现出强大的增长潜力，得益于其创新的 Cu-SAR-bisPSMA 前列腺癌治疗平台。最近的试验进展显示出良好的疗效和安全性，重度预处理参与者的 PSA 显著降低。FDA 的快速通道认证支持加速开发。尽管截至 2024 年 12 月的半年净亏损为 2358 万澳元，但收入从 652 万澳元增长至 1094 万澳元，预测显示收入增长迅速，超过市场平均水平。</p>
</div><ul>
<li>Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report.</li>
<li>Our valuation report here indicates Clarity Pharmaceuticals may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的盈利增长报告中更深入地了解 Clarity Pharmaceuticals 的潜力。</li>
<li>我们的估值报告显示 Clarity Pharmaceuticals 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth"/></p>
<p>ASX:CU6 Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:CU6 盈利和收入增长</p>
</div><h2>IperionX (ASX:IPX)</h2>
<div class="lb-trans"><h2>IperionX (ASX:IPX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> IperionX Limited is involved in the exploration and development of mineral properties in the United States, with a market capitalization of approximately A$900.03 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> IperionX Limited 专注于在美国的矿产资源勘探和开发，市值约为 9 亿澳元。</p>
</div><p><strong>Operations:</strong> IperionX Limited's revenue segments are not specified in the provided text.</p>
<div class="lb-trans"><p><strong>运营：</strong> 提供的文本中未具体说明 IperionX Limited 的收入部分。</p>
</div><p><strong>Insider Ownership:</strong> 19.2%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 19.2%</p>
</div><p>IperionX is poised for significant growth, driven by its Titan Critical Minerals Project in Tennessee and strategic U.S. partnerships, including a USD 47.1 million government award to enhance the titanium supply chain. Despite recent shareholder dilution and a net loss of USD 16.24 million for the half-year ending December 2024, IperionX's revenue is forecast to grow rapidly, outpacing market averages with expected profitability within three years, supported by innovative technologies and substantial insider ownership.</p>
<div class="lb-trans"><p>IperionX 凭借其在田纳西州的 Titan 关键矿产项目和战略性美国合作伙伴关系，正处于显著增长的有利位置，包括获得 4710 万美元的政府奖励以增强钛供应链。尽管最近股东稀释和截至 2024 年 12 月的半年净亏损为 1624 万美元，IperionX 的收入预计将迅速增长，超过市场平均水平，预计在三年内实现盈利，得益于创新技术和实质内部持股。</p>
</div><ul>
<li>Click here to discover the nuances of IperionX with our detailed analytical future growth report.</li>
<li>Our comprehensive valuation report raises the possibility that IperionX is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现 IperionX 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们的全面估值报告提出 IperionX 的定价可能高于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown"/></p>
<p>ASX:IPX Ownership Breakdown as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:IPX 持股结构</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该怎么办？</h2>
</div><ul>
<li>Click through to start exploring the rest of the 90 Fast Growing ASX Companies With High Insider Ownership now.</li>
<li>Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击进入，开始探索其余 90 家内部持股高的快速成长 ASX 公司。</li>
<li>考虑其他策略？这项技术可能取代计算机：发现 22 只股票正在努力使量子计算成为现实。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div><p>If you're looking to trade IperionX, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 IperionX，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

3 家 ASX 增长型公司，内部持股比例最高可达 23%